Auxiliis, a full-service contract research organisation (CRO) dedicated exclusively to paediatric clinical trials, has raised EUR 1.3 million from Alliance Jura Hongrie, a Budapest-based venture capital fund. The EUR 1.3 million investment – that is expected to reach a total of EUR 2.0 million by the end of this year – will be used to further advance the clinical development of new medicines for children.
New approach today, to improve children's health tomorrow
The recently changed pharmaceutical industry’s perspective - as a result of legislative initiatives in both Europe and US, and the increasing pressure from patients’ groups – created great opportunities for paediatric drug development. Combining its extensive expertise, direct access to approximately 20,000 young patients per year and the financial support of cooperation partners, Auxiliis is offering a new approach to paediatric clinical trials.
Maximising effectiveness and repositioning of existing therapies
Next to the comprehensive package of research services offered to the pharmaceutical industry, Auxiliis supports clinical trials of new therapies, as well as repositioning of currently existing therapies or abandoned drug development projects.
“The development of new drugs for children requires a set of specific competencies. With our therapeutic expertise, highly valued scientific team and dedicated involvement of more than 50 paediatricians, we believe that we can make a difference and improve children’s health. Our goal is to make Auxiliis the regional market leader in paediatric clinical research.” – jointly stated Dr Otto Skoran and Dr Wouter Wijker, Auxiliis’ Co-founders and Directors.
To explore overseas clinical research collaborations, Auxiliis has recently opened a representative office in Richmond, Virginia (USA). The investment of Alliance Jura Hongrie will be also used for further expanding Auxiliis’ operations and getting a foothold in the North American market.